Alexander Mayweg, Ph.D., is a Partner and also serves as head of Ridgeline Therapeutics, Versant’s Basel-based Discovery Engine. Alex is an accomplished leader in pharmaceutical drug discovery and medicinal chemistry across Europe, the U.S. and Asia. He brings to Versant deep operating capabilities, having led successful therapeutics portfolios, programs and teams within Roche Pharma Research and Early Development.
Alex joined Versant in 2016 from Roche where he served as global head of chemistry. Prior to Roche, Alex earned a Ph.D. in organic chemistry at Oxford University, followed by post-doctorate training at Stanford University. His undergraduate degree was in chemistry from the Imperial College in London.